{"id":18318,"date":"2015-12-21T14:00:09","date_gmt":"2015-12-21T13:00:09","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=18318"},"modified":"2015-12-21T14:00:09","modified_gmt":"2015-12-21T13:00:09","slug":"que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/","title":{"rendered":"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder"},"content":{"rendered":"<div align=\"center\">\n<p><iframe src=\"https:\/\/player.vimeo.com\/video\/149628985\" height=\"281\" width=\"500\" allowfullscreen=\"\" frameborder=\"0\"><\/iframe><\/p>\n<div align=\"\/center\">\n<p style=\"text-align: left;\"><strong>M\u00e9s de 21.500 persones es beneficien a Barcelona dels Sistemes Personalitzats de Dosificaci\u00f3 que ofereixen les farm\u00e0cies<\/strong>. <strong>Qu\u00e8 hi podria aportar la tecnologia a aquests dispositius?<\/strong> Aquesta \u00e9s una de les preguntes a les que va respondre Eran Shavelsky, fundador i CEO de Medminder, en l\u2019entrevista que li vam fer al Col\u00b7legi, aprofitant la seva visita a Barcelona el passat mes d\u2019octubre.<\/p>\n<p style=\"text-align: left;\"><strong>Als Estats Units l\u2019empresa ha desenvolupat uns dispositius electr\u00f2nics amb la mateixa finalitat que els SPD, per\u00f2 comptant amb el suport de la tecnologia<\/strong>. Amb l\u2019objectiu de garantir que els usuaris segueixin el tractament correctament aquests \u201cdispensadors de p\u00edndoles\u201d, tal com els defineixen, incorporen alertes tant visuals com sonores, i altres sistemes d\u2019av\u00eds, per exemple gravacions de veu que poden programar els familiars, fins i tot, telem\u00e0ticament. A m\u00e9s, permet fer el seguiment en l\u00ednia de com s&#8217;est\u00e0 prenent el pacient el tractament i detectar si hi ha hagut oblits i en quin moment.<\/p>\n<p style=\"text-align: left;\">Entre els principals beneficis, Shavelsky explica que amb aquest sistema han aconseguit una \u201c<strong>taxa de compliment del 95%\u201d <\/strong>per part dels pacients que l\u2019utilitzen, <strong>\u201cs\u2019estalvien hospitalitzacions\u201d i s\u2019ajuda a &#8220;mantenir la seva independ\u00e8ncia&#8221;<\/strong>.<\/p>\n<p style=\"text-align: left;\">Com podrien beneficiar-se els pacients a Catalunya? Qui estaria disposat a apostar per aquest servei? Qu\u00e8 podria aportar als farmac\u00e8utics? Aquestes s\u00f3n algunes de les preguntes que li va formular el tresorer del Col\u00b7legi, Joan Calduch, a l&#8217;ide\u00f2leg d&#8217;aquests dispositius per tal de poder compartir la seva experi\u00e8ncia amb vosaltres.<strong> Trobareu totes les respostes en aquest <a href=\"https:\/\/vimeo.com\/149628985\" target=\"_blank\" rel=\"noopener\">v\u00eddeo<\/a><\/strong>.<\/p>\n<p style=\"text-align: left;\"><span style=\"color: #808080;\">Els\u00a0<strong>Sistemes Personalitzats de Dosificaci\u00f3 (SPD)<\/strong>\u00a0permeten organitzar la medicaci\u00f3 dels pacients en funci\u00f3 del moment del dia en qu\u00e8 se l\u2019han de prendre, de manera que els hi resulti m\u00e9s f\u00e0cil fer-ho correctament. Amb la seva utilitzaci\u00f3 es busca evitar errors de medicaci\u00f3 i millorar l\u2019adher\u00e8ncia als tractaments.<\/span><span style=\"color: #808080;\"><br \/>\n<\/span><\/p>\n<p style=\"text-align: left;\"><strong>Enlla\u00e7os relacionats:<\/strong><\/p>\n<ul style=\"text-align: left;\">\n<li><a href=\"http:\/\/blog.cofb.cat\/1-doctubre-dia-internacional-de-la-gent-gran-els-farmaceutics-donen-eines-per-millorar-el-seguiment-dels-tractaments\/\" target=\"_blank\" rel=\"noopener\">1 d&#8217;octubre, Dia Internacional de la Gent Gran: els farmac\u00e8utics donen eines per millorar el seguiment dels tractaments<\/a> (Blog)<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/les-farmacies-catalanes-estudien-monitoritzar-a-pacients-cronics\/\" target=\"_blank\" rel=\"noopener\">Les farm\u00e0cies catalanes estudien monitoritzar a pacients cr\u00f2nic<\/a>s (Blog)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>M\u00e9s de 21.500 persones es beneficien a Barcelona dels Sistemes Personalitzats de Dosificaci\u00f3 que ofereixen les farm\u00e0cies. Qu\u00e8 hi podria aportar la tecnologia a aquests dispositius? Aquesta \u00e9s una de les preguntes a les que va respondre Eran Shavelsky, fundador i CEO de Medminder, en l\u2019entrevista que li vam fer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":18393,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[2187,2176,2216],"class_list":["post-18318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-adherencia","tag-cartera-de-serveis","tag-spd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"M\u00e9s de 21.500 persones es beneficien a Barcelona dels Sistemes Personalitzats de Dosificaci\u00f3 que ofereixen les farm\u00e0cies. Qu\u00e8 hi podria aportar la tecnologia a aquests dispositius? Aquesta \u00e9s una de les preguntes a les que va respondre Eran Shavelsky, fundador i CEO de Medminder, en l\u2019entrevista que li vam fer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-12-21T13:00:09+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder\",\"datePublished\":\"2015-12-21T13:00:09+00:00\",\"dateModified\":\"2015-12-21T13:00:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/\"},\"wordCount\":376,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"adher\u00e8ncia\",\"cartera de serveis\",\"SPD\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/\",\"name\":\"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-12-21T13:00:09+00:00\",\"dateModified\":\"2015-12-21T13:00:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/","og_locale":"ca_ES","og_type":"article","og_title":"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"M\u00e9s de 21.500 persones es beneficien a Barcelona dels Sistemes Personalitzats de Dosificaci\u00f3 que ofereixen les farm\u00e0cies. Qu\u00e8 hi podria aportar la tecnologia a aquests dispositius? Aquesta \u00e9s una de les preguntes a les que va respondre Eran Shavelsky, fundador i CEO de Medminder, en l\u2019entrevista que li vam fer [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2015-12-21T13:00:09+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder","datePublished":"2015-12-21T13:00:09+00:00","dateModified":"2015-12-21T13:00:09+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/"},"wordCount":376,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage"},"thumbnailUrl":"","keywords":["adher\u00e8ncia","cartera de serveis","SPD"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/","url":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/","name":"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-12-21T13:00:09+00:00","dateModified":"2015-12-21T13:00:09+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2015\/12\/21\/que-pot-aportar-la-tecnologia-al-compliment-dels-tractaments-entrevista-a-eran-shavelsky-fundador-de-medminder\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Qu\u00e8 pot aportar la tecnologia al compliment dels tractaments? Entrevista a Eran Shavelsky, fundador de Medminder"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"M\u00e9s de 21.500 persones es beneficien a Barcelona dels Sistemes Personalitzats de Dosificaci\u00f3 que ofereixen les farm\u00e0cies. Qu\u00e8 hi podria aportar la tecnologia a aquests dispositius? Aquesta \u00e9s una de les preguntes a les que va respondre Eran Shavelsky, fundador i CEO de Medminder, en l\u2019entrevista que li vam fer [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/18318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=18318"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/18318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=18318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=18318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=18318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}